Biogen, listed on NASDAQ under the ticker BIIB, has been downgraded by Argus from a Buy to a Hold rating. This decision is based on anticipated declines in profit per share by 2025. In February, Biogen projected its non-GAAP earnings per share for 2025 to be within the range of $15.25 to $16.25. The company also forecasted a mid-single-digit decrease in total revenue, attributing this decline to factors related to multiple sclerosis.
Argus Downgrades Biogen to Hold Due to Expected Profit Decline
Related stories
Latest News
Megyn Kelly Excels in Podcast Journalism
Megyn Kelly is poised to enter new territory in...
Technology
‘Mythic Quest’ to Conclude with Revised Season 4 Finale
"Mythic Quest," the workplace comedy on Apple TV+ about...
Business
Trump Exempts Smartphones, Chips, and Computers from Major Reciprocal Tariffs
Late Friday night, the US Customs and Border Protection...
Technology
Batman Gets a Tokusatsu Twist from Radiant Black’s Creators
Batman is continuously being reinvented, with recent transformations including...
Latest News
Sunday Preview: Trump Tariff Turmoil Continues; GOP Faces Budget Strains
President Trump's recent tariff agenda has continued to cause...

DMN8 Partnershttps://salvonow.com/
DMN8 Partners utilizes a strategy of Cross Channel marketing including local search engine optimization, PPC, messaging and hyper-targeted audiences allow our clients to experience results and ROI that fuel growth and expansion in their operations. There are a lot of digital marketing options across the country but partnering with an agency that understands multiple touches on multiple platforms allows your company’s message to be seen at the perfect time, on the perfect platform, by your perfect prospect. DMN8 Partners has had years of experience growing businesses. Start growing your business today and begin DOMINATE-ing your market.